Legato Capital Management LLC Has $277,000 Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

Legato Capital Management LLC lowered its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 60.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 10,395 shares of the company’s stock after selling 15,890 shares during the quarter. Legato Capital Management LLC’s holdings in Castle Biosciences were worth $277,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in CSTL. The Manufacturers Life Insurance Company raised its holdings in shares of Castle Biosciences by 7.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,122 shares of the company’s stock worth $220,000 after acquiring an additional 675 shares during the last quarter. Truist Financial Corp raised its holdings in shares of Castle Biosciences by 20.5% in the 2nd quarter. Truist Financial Corp now owns 14,217 shares of the company’s stock worth $310,000 after acquiring an additional 2,420 shares during the last quarter. Creative Planning acquired a new stake in shares of Castle Biosciences in the 3rd quarter worth about $299,000. First Bank & Trust acquired a new stake in shares of Castle Biosciences in the 3rd quarter worth about $261,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Castle Biosciences by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,335 shares of the company’s stock worth $152,000 after acquiring an additional 2,093 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Buying and Selling at Castle Biosciences

In other news, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total transaction of $221,613.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Derek J. Maetzold sold 9,364 shares of the stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $28.34, for a total transaction of $265,375.76. Following the transaction, the insider now directly owns 84,762 shares of the company’s stock, valued at $2,402,155.08. This represents a 9.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,771 shares of company stock worth $886,112. Insiders own 7.20% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Scotiabank upped their target price on shares of Castle Biosciences from $37.00 to $44.00 and gave the stock a “sector outperform” rating in a report on Wednesday, November 6th. Canaccord Genuity Group upped their target price on shares of Castle Biosciences from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. KeyCorp upped their target price on shares of Castle Biosciences from $28.00 to $36.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Lake Street Capital upped their target price on shares of Castle Biosciences from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Finally, Stephens reiterated an “overweight” rating and issued a $41.00 price objective on shares of Castle Biosciences in a research note on Thursday, January 2nd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $40.29.

Castle Biosciences Trading Down 1.1 %

NASDAQ:CSTL opened at $27.32 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. The firm has a market cap of $765.23 million, a price-to-earnings ratio of 136.61 and a beta of 0.91. Castle Biosciences, Inc. has a 52 week low of $16.97 and a 52 week high of $35.84. The firm has a 50-day moving average price of $27.91 and a two-hundred day moving average price of $29.06.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.